{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:35:29Z","timestamp":1784529329083,"version":"3.55.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We describe a case of limb-threatening osteomyelitis and metalware infection with carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa successfully cured with aggressive surgical debridement and combined intravenous fosfomycin and colistin. Real-time therapeutic drug monitoring was used to maximize probability of efficacy and minimize potential for toxicity.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa572","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T18:48:54Z","timestamp":1606416534000},"source":"Crossref","is-referenced-by-count":7,"title":["Cure of Limb-Threatening XDR <i>Pseudomonas aeruginosa<\/i> Infection: Combining Genome Sequencing, Therapeutic Drug Level Monitoring, and Surgical Debridement"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6667-2868","authenticated-orcid":false,"given":"Shanti","family":"Narayanasamy","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-8590","authenticated-orcid":false,"given":"Roger L","family":"Nation","sequence":"additional","affiliation":[{"name":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A","family":"Mahony","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Lindsay","family":"Grayson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Melbourne, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Melbourne, Australia"},{"name":"Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne at the Doherty Institute for Infection & Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norelle L","family":"Sherry","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Melbourne, Australia"},{"name":"Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne at the Doherty Institute for Infection & Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Khumra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Melbourne, Melbourne, Australia"},{"name":"Department of Clinical Pharmacology, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert G","family":"Frauman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Melbourne, Melbourne, Australia"},{"name":"Department of Clinical Pharmacology, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha E","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Melbourne, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"2021012918355277300_CIT0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2021012918355277300_CIT0002","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"CLSI","year":"2020"},{"key":"2021012918355277300_CIT0003","doi-asserted-by":"crossref","first-page":"e00573","DOI":"10.1128\/JCM.00573-19","article-title":"Genomics for molecular epidemiology and detecting transmission of carbapenemase-producing Enterobacterales in Victoria, Australia, 2012 to 2016","volume":"57","author":"Sherry","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2021012918355277300_CIT0004","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"2021012918355277300_CIT0005","article-title":"Seemann T. Shovill GitHub Repository"},{"key":"2021012918355277300_CIT0006","author":"Seemann"},{"key":"2021012918355277300_CIT0007","author":"Seemann"},{"key":"2021012918355277300_CIT0008","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1099\/jmm.0.001106","article-title":"First detected OXA-50 carbapenem-resistant clinical isolates Pseudomonas aeruginosa from Bulgaria and interplay between the expression of main efflux pumps, OprD and intrinsic AmpC","volume":"68","author":"Petrova","year":"2019","journal-title":"J Med Microbiol"},{"key":"2021012918355277300_CIT0009","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2021012918355277300_CIT0010","first-page":"565","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021012918355277300_CIT0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2021012918355277300_CIT0012","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jac\/dkx399","article-title":"Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model","volume":"73","author":"Cai","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021012918355277300_CIT0013","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1179\/joc.2004.16.3.282","article-title":"Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections","volume":"16","author":"Tascini","year":"2004","journal-title":"J Chemother"},{"key":"2021012918355277300_CIT0014"},{"key":"2021012918355277300_CIT0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021012918355277300_CIT0016","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/cid\/civ964","article-title":"Updated US and European dose recommendations for intravenous colistin: how do they perform?","volume":"62","author":"Nation","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021012918355277300_CIT0017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14787210.2019.1573669","article-title":"Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?","volume":"17","author":"Dimopoulos","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021012918355277300_CIT0018","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2021012918355277300_CIT0019","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for treatment of prostatitis: new tricks for old dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021012918355277300_CIT0020","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ijantimicag.2018.09.008","article-title":"Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia","volume":"52","author":"Khawcharoenporn","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0022","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijantimicag.2011.11.012","article-title":"Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin","volume":"39","author":"Apisarnthanarak","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0023","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"2021012918355277300_CIT0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","article-title":"Resistance to fosfomycin: mechanisms, frequency and clinical consequences","volume":"53","author":"Falagas","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021012918355277300_CIT0026","first-page":"30","article-title":"The role of fosfomycin in osteoarticular infection","volume":"32","author":"Morata","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2021012918355277300_CIT0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000221921","article-title":"Fosfomycin in osteomyelitis","volume":"22","author":"Fernandez-Valencia","year":"1976","journal-title":"Chemotherapy"},{"key":"2021012918355277300_CIT0028","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ijantimicag.2015.07.019","article-title":"The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic\/pharmacodynamic model experiments","volume":"46","author":"Albur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0029","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ja.2015.27","article-title":"In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa","volume":"68","author":"Di","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"2021012918355277300_CIT0030","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1128\/AAC.01718-12","article-title":"Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-\u03b2-lactamase-producing Escherichia coli in a foreign-body infection model","volume":"57","author":"Corvec","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012918355277300_CIT0031","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1093\/jac\/dkz257","article-title":"Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae","volume":"74","author":"Cr\u00e9mieux","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021012918355277300_CIT0032","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/jac\/dkv221","article-title":"In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa","volume":"70","author":"Walsh","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021012918355277300_CIT0033","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dky045","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model","volume":"73","author":"Bilal","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021012918355277300_CIT0034","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2021012918355277300_CIT0036","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","article-title":"Adverse events associated with intravenous fosfomycin","volume":"37","author":"Florent","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0037","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021012918355277300_CIT0038","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorl\u00ed","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2021012918355277300_CIT0039","article-title":"Pharmacokinetic\/toxicodynamic analysis of colistin-associated acute kidney injury in critically Ill patients","volume":"61:e01367-17","author":"Forrest","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012918355277300_CIT0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2021012918355277300_CIT0041","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"2021012918355277300_CIT0042","article-title":"Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity","volume":"8:24","author":"Nation","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"2021012918355277300_CIT0043","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/cir611","article-title":"Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system","volume":"53","author":"Pogue","year":"2011","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa572\/34550268\/ofaa572.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/1\/ofaa572\/36149785\/ofaa572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/1\/ofaa572\/36149785\/ofaa572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T18:36:05Z","timestamp":1611945365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa572\/6006732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa572","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,11,26]]},"article-number":"ofaa572"}}